A TREATMENT WITH RECOMBINANT HUMAN ERYTHROPOETIN BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION SIGNIFICANTLY REDUCES TRANSFUSION REQUIREMENT IN MULTIPLE MYELOMA PATIENTS


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles